Back to search results

Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Biliary Tract Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Research Site, Brisbane, Australia

  • Research Site, Melbourne, Australia

  • Research Site, Perth, Australia

  • Research Site, Sydney, Australia

  • Research Site, Aichi, Japan

  • National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

  • Research Site, Fukuoka, Japan

  • Research Site, Hokkaido, Japan

  • Kanagawa Cancer Center, Kanagawa, Japan

  • Research Site, Miyagi, Japan

  • Research Site, Osaka, Japan

  • Research Site, Tokyo, Japan

  • The Cancer Institute Hospital, Tokyo, Japan

  • Toyama University Hopspital, Toyama, Japan

  • Wakayama Medical University Hospital, Wakayama, Japan

  • Research Site, Busan, South Korea

  • Research Site, Hwasun, South Korea

  • Research Site, Seongnam, South Korea

  • Research Site, Seoul, South Korea

  • Research Site, Bangkok, Thailand

  • Research Site, Chiang Mai, Thailand

View source on ClinicalTrials.gov(opens in a new tab)